Zobrazeno 1 - 10
of 28
pro vyhledávání: '"D H, Vesole"'
Autor:
I. Avivi, D. H vesole, J. Dávila Valls, L. Usnarska-Zubkiewicz, V. Milunovic, B. B. Bogumiła Osękowska, A. Kopińska, M. Gentile, B. P. MARTÍNEZ, P. Robak, E. crusoe, R. LUIS GERARDO, M. Gajewska, V. Gergely, M. Delforge, Y. Cohen, G. Alessandro, C. peña, C. Shustik, G. Mikala, K. Žalac, A. H. Denis, B. Peter, K. Weisel, J. martinez lopez, A. Waszczuk-Gajda, M. Krzystanski, A. Jurczyszyn
Publikováno v:
HemaSphere, Vol 6, Pp 782-783 (2022)
Externí odkaz:
https://doaj.org/article/07b6cf6370f14b5ea5ab94db6464b393
Publikováno v:
Bone Marrow Transplantation. 51:492-500
Despite remarkable progress in survival with the availability of novel agents, an overwhelming majority of patients with multiple myeloma (MM) relapse and the curability of MM remains limited. Genetically defined high-risk MM represents a subgroup wi
Autor:
P. G. Richardson, C. C. Hofmeister, N. S. Raje, D. S. Siegel, S. Lonial, J. Laubach, Y. A. Efebera, D. H. Vesole, A. K. Nooka, J. Rosenblatt, D. Doss, M. H. Zaki, A. Bensmaine, J. Herring, Y. Li, L. Watkins, M. S. Chen, K. C. Anderson
Publikováno v:
Leukemia
This phase 1 dose-escalation study evaluated pomalidomide, bortezomib (subcutaneous (SC) or intravenous (IV)) and low-dose dexamethasone (LoDEX) in lenalidomide-refractory and proteasome inhibitor-exposed relapsed or relapsed and refractory multiple
Autor:
C. Fernández de Larrea, R. A. Kyle, B. G. M. Durie, H. Ludwig, S. Usmani, D. H. Vesole, R. Hajek, J. F. San Miguel, O. Sezer, P. Sonneveld, S. K. Kumar, A. Mahindra, R. Comenzo, A. Palumbo, A. Mazumber, K. C. Anderson, P. G. Richardson, A. Z. Badros, J. Caers, X. LeLeu, M. A. Dimopoulos, C. S. Chim, R. Schots, A. Noeul, D. Fantl, U. H. Mellqvist, O. Landgren, A. Chanan Khan, P. Moreau, R. Fonseca, G. Merlini, J. J. Lahuerta, J. Bladé, R. Z. Orlowski, J. J. Shah, on behalf of the International Myeloma Working Group [, CAVO, MICHELE, ZAMAGNI, ELENA
Publikováno v:
Leukemia, 27(4), 780-791. Nature Publishing Group
Fernández de Larrea, C, Kyle, R A, Durie, B G M, Ludwig, H, Usmani, S, Vesole, D H, Hajek, R, San Miguel, J F, Sezer, O, Sonneveld, P, Kumar, S K, Mahindra, A, Comenzo, R, Palumbo, A, Mazumber, A, Anderson, K C, Richardson, P G, Badros, A Z, Caers, J, Cavo, M, LeLeu, X, Dimopoulos, M A, Chim, C S, Schots, R, Noeul, A, Fantl, D, Mellqvist, U-H, Landgren, O, Chanan-Khan, A, Moreau, P, Fonseca, R, Merlini, G, Lahuerta, J J, Bladé, J, Orlowski, R Z, Shah, J J & International Myeloma Working Group 2013, ' Plasma cell leukemia : consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group ', Leukemia Insights, vol. 27, no. 4, pp. 780-91 . https://doi.org/10.1038/leu.2012.336
Digital.CSIC. Repositorio Institucional del CSIC
instname
Fernández de Larrea, C, Kyle, R A, Durie, B G M, Ludwig, H, Usmani, S, Vesole, D H, Hajek, R, San Miguel, J F, Sezer, O, Sonneveld, P, Kumar, S K, Mahindra, A, Comenzo, R, Palumbo, A, Mazumber, A, Anderson, K C, Richardson, P G, Badros, A Z, Caers, J, Cavo, M, LeLeu, X, Dimopoulos, M A, Chim, C S, Schots, R, Noeul, A, Fantl, D, Mellqvist, U-H, Landgren, O, Chanan-Khan, A, Moreau, P, Fonseca, R, Merlini, G, Lahuerta, J J, Bladé, J, Orlowski, R Z, Shah, J J & International Myeloma Working Group 2013, ' Plasma cell leukemia : consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group ', Leukemia Insights, vol. 27, no. 4, pp. 780-91 . https://doi.org/10.1038/leu.2012.336
Digital.CSIC. Repositorio Institucional del CSIC
instname
PMCID: PMC4112539.-- International Myeloma Working Group: et al.
Plasma cell leukemia (PCL) is a rare and aggressive variant of myeloma characterized by the presence of circulating plasma cells. It is classified as either primary PCL occurring a
Plasma cell leukemia (PCL) is a rare and aggressive variant of myeloma characterized by the presence of circulating plasma cells. It is classified as either primary PCL occurring a
Autor:
Reinhold Munker, Heather Landau, Matt Kalaycio, Siddhartha Ganguly, R. T. Kamble, Mohamed A. Kharfan-Dabaja, William A. Wood, Aparna Krishnan, Ayman Saad, Miguel Pérez, Natalie S. Callander, Robert F. Cornell, Angela Dispenzieri, Harry C. Schouten, Cesar O. Freytes, Parameswaran Hari, Richard F. Olsson, Anita D'Souza, Shaji Kumar, Morie A. Gertz, Manish Sharma, Jason Tay, Dan T. Vogl, KC Anderson, L. B. To, Mei-Jie Zhang, Bipin N. Savani, John L. Wagner, Angelo Maiolino, David I. Marks, Mehdi Hamadani, Alfred L. Garfall, Cindy Lee, D. H. Vesole, John Gibson, Luciano J. Costa, Tomer M Mark, Jiaxing Huang, Baldeep Wirk, Tulio E. Rodriguez, Robert Peter Gale, Sachiko Seo, Hillard M. Lazarus, Edward A. Stadtmauer, Gary J. Schiller, Emma C. Scott, Robert A. Kyle, Jeffrey Schriber, Taiga Nishihori, Muthalagu Ramanathan, Christopher Bredeson, Geoffrey L. Uy
Publikováno v:
Bone marrow transplantation
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Bone Marrow Transplantation, 50(12). Nature Publishing Group
Bone marrow transplantation, vol 50, iss 12
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Bone Marrow Transplantation, 50(12). Nature Publishing Group
Bone marrow transplantation, vol 50, iss 12
In patients with multiple myeloma (MM) undergoing autologous hematopoietic cell transplantation (auto-HCT), peripheral blood progenitor cells (PBPCs) may be collected following mobilization with growth factor alone (GF) or cytotoxic chemotherapy plus
Autor:
A. Bashey, Patrick J. Stiff, R. P. Gale, Mei-Jie Zhang, G. L. Phillips, John R. Wingard, J. Gibson, A. D. Rubin, B. J. Bolwell, E. Montserrat, B. Yanes, R. H. Herzig, J. W. Fay, James O. Armitage, D. H. Vesole, W. Hiddemann, Mary M. Horowitz, L. J. Burns, A. Keating, I. Bence-Bruckler, S. Goldstein, K. Van Besien, Sergio Giralt, C. O. Freytes, D. P. Schenkein, Julie M. Vose, Hillard M. Lazarus, A. Miller, R. Martino, G. Milone, P. A. Rowlings, S. Pavlovsky, Philip L. McCarthy, A A Pecora
Publikováno v:
Journal of Clinical Oncology. 19:406-413
PURPOSE: To evaluate the results of high-dose chemotherapy and autologous hematopoietic stem-cell transplantation (autotransplants) in patients with diffuse aggressive non-Hodgkin’s lymphoma (NHL) who never achieve a complete remission with convent
Autor:
K R, Desikan, G, Tricot, N C, Munshi, E, Anaissie, D, Spoon, A, Fassas, A, Toor, M, Zangari, A, Badros, C, Morris, D H, Vesole, D, Siegel, S, Jagannath, B, Barlogie
Publikováno v:
British journal of haematology. 112(1)
Haematopoietic growth factors, especially granulocyte colony-stimulating factor (G-CSF), are frequently utilized alone for peripheral blood stem cell (PBSC) procurement to avoid the morbidity associated with high-dose chemotherapy (HDT). Moreover, th
Publikováno v:
British journal of haematology. 107(2)
Tumour lysis syndrome (TLS) in plasma cell dyscrasias is extremely rare. TLS has been described in eight cases of multiple myeloma undergoing high-dose therapy with autologous stem cell transplant (ASCT). Recently, clinical trials of intensive chemot
Autor:
W R, Drobyski, M J, Hessner, J P, Klein, C, Kabler-Babbitt, D H, Vesole, D A, Margolis, C A, Keever-Taylor
Publikováno v:
Blood. 94(2)
T-cell depletion (TCD) of the donor marrow graft has been shown to reduce the severity of graft-versus-host disease (GVHD) in patients with chronic-phase (CP) chronic myelogenous leukemia (CML) undergoing HLA-identical sibling allogeneic marrow trans
Autor:
D H, Vesole
Publikováno v:
Cancer treatment and research. 99